---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007732"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T09:27:01.826707+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma closes SPAC merger, lists on Nasdaq; enters $100M equity line

## Summary
- Completed business combination with PowerUp Acquisition Corp.; began trading on Nasdaq Feb 20 under ASBP/ASBPW.
- Proceeds from transaction total approx $3.8M including trust account and PIPE financing.
- Entered $100M ELOC agreement with Arena; 96% of VWAP with $4.00 floor; 1,893,473 commitment shares issued.
- Lead product is fast-absorbing aspirin for cardiology emergencies; plans FDA fast track 505(b)(2) NDA.
- Management led by CEO Kraig Higginson; board of seven directors including Michael Howe, Gary E. Stein.

## SEC filing metadata
- accession: 0001493152-25-007732
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315225007732/0001493152-25-007732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315225007732/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007732
- JSON: https://secwatch.observer/filing/0001493152-25-007732.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.